Ordesekimab is under clinical development by Amgen and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ordesekimab’s likelihood of approval (LoA) and phase transition for Celiac Disease took place on 02 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ordesekimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ordesekimab overview

AMG-714 (HuMax-IL15) is under development for the treatment of vitiligo, gluten-free diet non-responsive celiac disease and refractory celiac disease. It is administered through subcutaneous and intravenous routes in the form of solution. AMG 714 is a fully human monoclonal antibody, directed against interleukin-15 (IL-15).  It was also under development for the treatment of rheumatoid arthritis and moderate to severe psoriasis.

Amgen overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.

Quick View Ordesekimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Ordesekimab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Immunology
Key Developers
  • Sponsor Company: Amgen
  • Originator: Genmab
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.